ClinicalTrials.gg
Not yet recruitingNCT07856160Updated Nov 18, 2026

De-escalation of Axillary Dissection for Node-positive Breast Cancer

An interventional study of TAD and ALND in Breast Cancer by AJCC V8 Anatomic Stage and Breast Cancer, sponsored by University of Nebraska. Not yet recruiting. Open to female participants aged 19 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Nebraska · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 18, 2026Start date movedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
19 Years to 99 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Breast Neoplasms by University of Nebraska — 3 open to participants now, 4 under way, none of them phase 3. Breast Neoplasms · University of Nebraska.

Planned enrollment
10th of 17
20 · median 24
Started
2027
the only one that year
No phase
9 of 21
2 open now
Registered
21st of 21
by date

Among the 21 studies in Breast Neoplasms by University of Nebraska, this one is the 10th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2027, is one of 9 with no phase, and was the 21st registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 21 studies in Breast Neoplasms by University of Nebraska are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 19 Years to 99 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Breast Neoplasms by University of Nebraska, or all of them as a file.
02

Study summary

Recent studies have demonstrated the safety of de-escalation of nodal surgery for clinically node-positive breast cancer patients after a favorable response to neoadjuvant systemic therapy (NST). These studies excluded patients with clinically node-positive stage 2 or 3 (cN2, cN3) disease. Consequently, the current guidelines recommend axillary lymph node dissection (ALND) for patients with cN2/cN3 breast cancer, even after a favorable response to NST. Many cN2/cN3 patients achieve nodal pathologic complete response (pCR) after NST, and this has raised interest in less invasive surgical approaches for the management of the axilla in this setting. We aim to evaluate the pathologic concordance between lymph node status post neoadjuvant therapy (ypN) derived from targeted axillary dissection (TAD) and ALND performed sequentially under the same anesthesia in patients with cN2/cN3 who convert to clinically node-negative (ycN0) following completion of NST. If a high level of concordance is determined between the ypN status determined from the TAD and the ALND, our next step would be to expand the trial to include a larger number of patients, making it multi-institutional, in order to power the study for more meaningful analysis.

03

Conditions studied

  • Breast Cancer by AJCC V8 Anatomic Stage
  • Breast Cancer

Browse trials for

Keywords

  • ALND
  • Sentinel Lymph Node Biopsy
  • TAD
  • Axillary
  • cN2
  • cN3
04

Who can participate

Ages eligible
19 Years to 99 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Females
  2. Aged ≥ 19 years old at time of study entry.
  3. Patient must be able to provide study-specific prior to study enrolment.
  4. Histological confirmation of breast cancer diagnosis on core needle . Pathology will be confirmed by internal UNMC review if the biopsy was completed at an outside institution.
  5. Clinical and/or radiographic cT1-T4 N2-3 M0 disease.
  6. Patients must complete NST. Patients who complete all recommended cycles of NST, regardless of dose reductions, are eligible.
  7. Clinical and radiographic (breast MRI with and without contrast) re-evaluation following completion of NST.
  8. Achievement of a complete clinical and radiographic nodal response (ycN0).

Exclusion criteria

Exclusion Criteria:

  1. Patients with disease at presentation.
  2. Patients unable to complete the recommended NST.
  3. Patients who are pregnant.
  4. Patients with a known allergic reaction to injectable blue dye.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Treatment

    TAD + ALND

    Procedure: TAD · Procedure: ALND

Interventions

  • ProcedureTAD

    Targeted axillary dissection

  • ProcedureALND

    Axillary lymph node dissection

06

What researchers measure

Primary outcomes

  1. Pathologic nodal status (ypN) derived from targeted axillary dissection (TAD) and axillary lymph node dissection (ALND.)

    Pathologic concordance between pathologic nodal status derived from TAD and ALND will be determined based on the pathological results of the two specimens collected.

    Time frame: 1 month

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2031, 48 months later.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 48 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Oct 2026 → Jan 2027, primary completion Oct 2030 → Jan 2031 and completion Nov 2031 → Feb 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartEst.
Jan 15, 2027was Oct 2026
Primary completionEst.
Jan 15, 2031was Oct 2030
CompletionEst.
Feb 15, 2032was Nov 2031
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 15, 2026→Jan 15, 2027
Nov 18, 2026
Primary completion
Oct 15, 2030→Jan 15, 2031
Nov 18, 2026
Study completion
Nov 15, 2031→Feb 15, 2032
Nov 18, 2026
Interventions
Changed TAD+ALND→TAD. Added Procedure: ALND
Nov 5, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedTo evaluate the pathologic concordance between pathologicPathologic nodal status (ypN) derived from targeted axillary dissection (TAD) and axillary lymph node dissection (ALND.)Time frame: 1 month
Nov 5, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 3 updates
  1. Nov 18, 2026
    Start date Oct 15, 2026→Jan 15, 2027
    Primary completion Oct 15, 2030→Jan 15, 2031
    Study completion Nov 15, 2031→Feb 15, 2032
  2. Nov 5, 2026
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedTo evaluate the pathologic concordance between pathologicPathologic nodal status (ypN) derived from targeted axillary dissection (TAD) and axillary lymph node dissection (ALND.)Time frame: 1 month
    Interventions Changed TAD+ALND→TAD. Added Procedure: ALND
  3. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856160
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Jan 15, 2027 (estimated)
Primary completion
Jan 15, 2031 (estimated)
Completion
Feb 15, 2032 (estimated)
Last update
Nov 18, 2026

Study contacts

IIT Office, MA
Contact
IITOffice@unmc.edu
402-559-4596
Janelle-Cheri Millen, MBBS
principal investigator · University of Nebraska

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion